US20040186172A1 - Oxaliplatin active substance with a very low content of oxalic acid - Google Patents
Oxaliplatin active substance with a very low content of oxalic acid Download PDFInfo
- Publication number
- US20040186172A1 US20040186172A1 US10/482,367 US48236703A US2004186172A1 US 20040186172 A1 US20040186172 A1 US 20040186172A1 US 48236703 A US48236703 A US 48236703A US 2004186172 A1 US2004186172 A1 US 2004186172A1
- Authority
- US
- United States
- Prior art keywords
- oxalic acid
- oxaliplatin
- active substance
- water
- trans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
Definitions
- the present invention relates to an oxaliplatin active substance for a pharmaceutical composition, which active substance has a very low content of oxalic acid, to a process for preparing said active substance, to the use thereof for preparing a pharmaceutical composition, in particular by dissolving thereof in an aqueous medium, and to pharmaceutical compositions thereby obtained, notably in the form of a lyophilisat formulation, a liquid formulation or a sustained release formulation for parenteral or oral administration.
- Oxaliplatin or cis-oxalato(trans-/-1,2-diaminocyclohexane)-platinum (II) (CAS RN: 61825-94-3), is a diamine cyclohexane platinum derivative which is active in several solid tumour types such as colorectal cancers.
- PCT Patent Publication No. 99/43355 discloses the stabilizing effect of adding oxalic acid as a buffering agent to oxaliplatin aqueous pharmaceutical formulations.
- the present invention is based on the unexpected discovery by the Applicant that oxaliplatin active substance which contains a very small amount of oxalic acid, e.g. a weight content of about 0.40% or 0.20%, has a significantly higher in vivo toxicity than oxaliplatin active substance without detectable oxalic acid or with a weight content of oxalic acid of not more 0.08%.
- the problem addressed by the invention is to find an oxaliplatin active substance and a process for preparing that active substance, wherein a pharmaceutical composition containing that active substance has a reduced toxicity.
- the invention thus relates to an oxaliplatin active substance for a pharmaceutical composition, wherein its weight content in oxalic acid is not more than 0.08%, in particular not more than 0.05%, most preferably less than 0.02%.
- That oxaliplatin active substance may be prepared by a process close to that described in U.S. Pat. No. 5,290,961, which further includes compared to either of those processes, washing 2 to 5 times with water having a pH 4.5-7.0 the oxaliplatin crystals separated by filtration after reaction with alkali metal salt of oxalic acid, and washing 2 to 5 times the recrystallised crystals with water having a pH 4.5-7.0, the amount of water being used in those washings being sufficient for attaining the desired weight content in oxalic acid.
- the invention thus also concerns a process for preparing the above-defined active substance comprising the following steps
- step (d) or step (e) the appropriate volume of water having a pH 4.5-7.0 used at each washing in step (d) or step (e) in view of the desired content of oxalic acid in the oxaliplatin active substance and the acceptable yield in oxaliplatin. That volume is generally not more than 10 ml per gram of active substance.
- the respective content of residual oxalic acid in each crop is quantified by an appropriate high performance liquid chromatography method.
- the above-defined oxaliplatin active substance may be used for preparing a pharmaceutical composition useful in cancer treatment which presents a reduced toxicity compared to pharmaceutical compositions prepared using an oxaliplatin active substance of the prior art.
- the preparation of such a pharmaceutical composition includes the step of dissolving the active substance in an aqueous medium.
- the invention is thus related to the use of the above oxaliplatin active substance for preparing a pharmaceutical composition, to a process for preparing the same comprising the step of dissolving the active substance in an aqueous medium, to a pharmaceutical composition obtainable by that process and to a new pharmaceutical composition which contains that active substance, along with pharmaceutically acceptable excipients.
- the oxalic acid weight content may be higher when the oxaliplatin active substance is in aqueous medium than when it is in anhydrous state.
- the pharmaceutical composition may be a lyophilisate pharmaceutical formulation for parenteral or oral administration.
- a formulation is conveniently obtained by completely dissolving, at a temperature about 40° C. and under stirring, oxaliplatin in a solution of an excipient such as lactose monohydate in sterile water, then filtering once for clarification and one or more times for sterilisation, aliquoting the filtrate solution into vials and performing freeze-drying using cycles of freezing, primary drying (sublimation) and secondary drying according to techniques well known in the art.
- the weight content of oxalic acid in the lyophilisate pharmaceutical formulation is preferably not more than 0.60%, more preferably not more than 0.30%, most preferably not more than 0.20%.
- the pharmaceutical composition may also be a liquid pharmaceutical formulation for parenteral administration.
- a liquid pharmaceutical formulation for parenteral administration is generally obtained by completely dissolving oxaliplatin in sterile water, at a temperature about 40° C. and under stirring, then filtering once for clarification and one or more times for sterilisation, as described in PCT Patent Publication No. 96/04904.
- the weight content of oxalic acid in the liquid pharmaceutical formulation is preferably not more than 0.60%, more preferably not more than 0.30%, in particular not more than 0.20%.
- the pharmaceutical composition may also be a sustained release formulation including biodegradable polymeric material, notably in the form of microparticles, microspheres, microgranules, implants or gels.
- a sustained release formulation including biodegradable polymeric material, notably in the form of microparticles, microspheres, microgranules, implants or gels.
- Preparation of such an oxaliplatin sustained release formulation may be performed according to techniques well known in the art, with the limitation that all steps must be performed at a pH where the oxaliplatin active substance is stable, preferably between 4,5 and 7.0.
- An example of an appropriate method for preparing a sustained release formulation of microspheres is the process for preparing oxaliplatin encapsulating poly(D,L-lactide-co-glycolide)/poly(D,L-lactide) (PLGA/PLA) microspheres described in PCT Patent Publication No. 02/28386.
- the weight content of oxalic acid in the oxaliplatin active substance was determined using a hereafter briefly described specific ion-pair reverse phase HPLC test which has a detection limit of 0.02 w/w % for oxalic acid.
- the test solution consists of oxaliplatin dissolved using sonication at the concentration of 2 mg/ml in water.
- the specific ion-pair reverse phase HPLC test is conducted at pH 6.0 ⁇ 0.05 and a temperature of 40° C.
- oxaliplatin active substance (as obtained in Example 1) necessary to obtain a final concentration for example of 5 mg/ml is separately weighed, then added in preheated sterile water to the sterile water in the glass or inox container.
- the weighing container is rinsed three times with sterile water, the rinsing solution being added to the above mixture.
- the latter is stirred at the above temperature during 30 to 60 minutes, until complete dissolution of oxaliplatin.
- the water is bubbled with nitrogen to lower its oxygen content.
- the volume or weight of the solution is adjusted to its desired value by adding sterile water.
- the solution is stirred at 40 ⁇ 5° C. during about 10 minutes then cooled to 30° C. under stirring. Samples of the solution are then collected for the usual control tests.
- the solution is then subjected to aseptic filtration on a 0.2 ⁇ m membrane or alternatively autoclaving under conditions close to those described in European Pharmacopia 1997 Edition page 283-284 (minimum of 121° C. for 15 minutes). The solution is kept at 15-30° C. before being conditioned.
- the oxaliplatin solution for example at 5 mg/ml is then aseptically and preferably under nitrogen atmosphere conditioned in 5 ml cylindrical vials (volume of added solution about 4 ml corresponding to 20 mg available oxaliplatin), 15 ml cylindrical vials (volume of added solution about 10 ml corresponding to 50 mg available oxaliplatin), and 25 ml cylindrical vials (volume of added solution about 20 ml corresponding to 100 mg available oxaliplatin).
- oxaliplatin active substance (as obtained in Example 1) necessary to obtain a final concentration for example of 5 mg/ml is separately weighed, then added in preheated sterile water to the sterile water in the glass or inox container.
- the weighing container is rinsed three times with sterile water, the rinsing solution being added to the above mixture.
- the latter is stirred at the above temperature during 30 to 60 minutes, until complete dissolution of oxaliplatin.
- the water is bubbled with nitrogen to lower its oxygen content.
- the volume or weight of the solution is adjusted to its desired value by adding sterile water.
- the solution is stirred at 40 ⁇ 5° C. during about 10 minutes then cooled to 15-30° C. under stirring. Samples of the solution are then collected for the usual control tests.
- the solution is subjected to aseptic filtration on a 0.2 ⁇ m membrane, then aseptically filled into 50 ml cylindrical vials to give 100 mg oxaliplatin per vial. Freeze-drying is performed using cycles of freezing, primary drying (sublimation) and secondary drying, according to techniques well known in the art.
- the vials containing the lyophilisate pharmaceutical formulation are stoppered and sealed.
- Lethal doses LD 10 of a cytostatic active substance determinated in mice is generally considered as being a significative correlation with the maximum tolerated doses (MTD) in man.
- a first group of CD-1 mice has received a solution of the oxaliplatin active substance as obtained in Example 1 and LD 10 is around 18.0 mg7kg.
- a second group of animals has received the same solution as for the first group, but with the addition of oxalic acid at a final concentration of 0.2 mM, and LD 10 is around 14.4.
- LD10 along with clinical symptoms demonstrate that the oxaliplatin active substance as obtained in Example 4, while administrated in solution, is less toxic as the same active substance, but administrated with oxalic acid.
Abstract
Description
- The present invention relates to an oxaliplatin active substance for a pharmaceutical composition, which active substance has a very low content of oxalic acid, to a process for preparing said active substance, to the use thereof for preparing a pharmaceutical composition, in particular by dissolving thereof in an aqueous medium, and to pharmaceutical compositions thereby obtained, notably in the form of a lyophilisat formulation, a liquid formulation or a sustained release formulation for parenteral or oral administration.
- Oxaliplatin (INN) or cis-oxalato(trans-/-1,2-diaminocyclohexane)-platinum (II) (CAS RN: 61825-94-3), is a diamine cyclohexane platinum derivative which is active in several solid tumour types such as colorectal cancers.
- The molecular structure of that compound and its pharmaceutical properties were first disclosed by Kidani et al. in J. Med. Chem., 1978, 21, 1315, and in U.S. Pat. No. 4,169,846. The proposed general recipe to prepare that compound leads to the compound with such a low yield that it could not be envisaged to be performed on an industrial scale. Improved methods for synthesizing oxaliplatin were then disclosed in the patent literature (see e.g. U.S. Pat. Nos. 5,290,961, 5,298,642 and 5,338,874, European Patent Publications Nos. 625523 and 801070).
- All these published methods of synthesis of oxaliplatin include as last step the substitution in an aqueous solution of the two aquo ligands on Pt (II) by dicarboxylate coming from oxalic acid or an oxalate salt, that step being conducted in a slight excess of oxalic acid or oxalate salt. In spite of a disclosed subsequent purification step there is some residual oxalic acid in the purified oxaliplatin.
- The presence of some residual oxalic acid in the oxaliplatin active substance obtained by such methods has however never been recognized as representing a problem although its relative toxicity was well documented in the literature.
- For example U.S. Pat. No. 5,290,961 and European Patent Publication No. 801070 describe processes of preparing oxaliplatin that is substantially free of impurities such as by-products containing silver ions, halogen atoms or a Pt (IV) complexes. Oxalic acid is not mentioned as an impurity.
- PCT Patent Publication No. 99/43355 discloses the stabilizing effect of adding oxalic acid as a buffering agent to oxaliplatin aqueous pharmaceutical formulations.
- Neurotoxicity is a severe dose-limiting side effect of oxaliplatin. F. Grolleau et al., 2001, “A possible explanation of a neurotoxic effect of anticancer agent oxaliplatin on neuronal voltage-gated sodium channels”, The American Physiological Society, 2293-2297, have shown in vitro on neuronal voltage-gated sodium channels that oxalate ions, which represent a major metabolite of oxaliplatin biotransformation, may be responsible for the neurotoxicity of that compound.
- The present invention is based on the unexpected discovery by the Applicant that oxaliplatin active substance which contains a very small amount of oxalic acid, e.g. a weight content of about 0.40% or 0.20%, has a significantly higher in vivo toxicity than oxaliplatin active substance without detectable oxalic acid or with a weight content of oxalic acid of not more 0.08%.
- The problem addressed by the invention is to find an oxaliplatin active substance and a process for preparing that active substance, wherein a pharmaceutical composition containing that active substance has a reduced toxicity.
- The above problem is solved by the invention as defined in the appended set of claims.
- The invention thus relates to an oxaliplatin active substance for a pharmaceutical composition, wherein its weight content in oxalic acid is not more than 0.08%, in particular not more than 0.05%, most preferably less than 0.02%.
- That oxaliplatin active substance may be prepared by a process close to that described in U.S. Pat. No. 5,290,961, which further includes compared to either of those processes, washing 2 to 5 times with water having a pH 4.5-7.0 the oxaliplatin crystals separated by filtration after reaction with alkali metal salt of oxalic acid, and washing 2 to 5 times the recrystallised crystals with water having a pH 4.5-7.0, the amount of water being used in those washings being sufficient for attaining the desired weight content in oxalic acid.
- The invention thus also concerns a process for preparing the above-defined active substance comprising the following steps
- (a) reacting in aqueous solution potassium tetrachloroplatinate K2PtCl4 with trans-/-1,2-cyclohexanediamine, such as to obtain dichloro(trans-/-1,2-cyclo-hexanediamine)-platinum (II);
- (b) adding 1.6 equivalents in respect to the compound obtained in (a) of silver nitrate, such as to obtain diaquo(trans-/-1,2-cyclohexanediamine)-platinum (II);
- (c) optionally adding to the obtained solution a catalytic amount of potassium iodide or sodium iodide, stirring and adding active carbon under stirring;
- (d) filtering and adding to the obtained filtrate alkali metal salt of oxalic acid such as lithium, sodium, potassium salt, preferably potassium salt, separating the oxaliplatin crystals formed by filtration and washing up to 5 times those crystals with water having a pH 4.5-7.0; and
- (e) purifying oxaliplatin by recrystallisation wherein the crystals are collected on a filter and washed up to 5 times with water having a pH 4.5-7.0, wherein the amount of water used in washing during steps (d) and (e) is sufficient to attain the desired weight content in oxalic acid.
- The person skilled in the art will readily select the appropriate volume of water having a pH 4.5-7.0 used at each washing in step (d) or step (e) in view of the desired content of oxalic acid in the oxaliplatin active substance and the acceptable yield in oxaliplatin. That volume is generally not more than 10 ml per gram of active substance. The respective content of residual oxalic acid in each crop is quantified by an appropriate high performance liquid chromatography method.
- The above-defined oxaliplatin active substance may be used for preparing a pharmaceutical composition useful in cancer treatment which presents a reduced toxicity compared to pharmaceutical compositions prepared using an oxaliplatin active substance of the prior art.
- Generally the preparation of such a pharmaceutical composition includes the step of dissolving the active substance in an aqueous medium.
- The invention is thus related to the use of the above oxaliplatin active substance for preparing a pharmaceutical composition, to a process for preparing the same comprising the step of dissolving the active substance in an aqueous medium, to a pharmaceutical composition obtainable by that process and to a new pharmaceutical composition which contains that active substance, along with pharmaceutically acceptable excipients. Due to the complex physicochemical interactions that take place in the aqueous medium, which may include dissociation to a low degree of oxaliplatin into oxalic acid and diaquo(trans-/-1,2-cyclohexanediamine)-platinum (II), the oxalic acid weight content may be higher when the oxaliplatin active substance is in aqueous medium than when it is in anhydrous state.
- The pharmaceutical composition may be a lyophilisate pharmaceutical formulation for parenteral or oral administration. Such a formulation is conveniently obtained by completely dissolving, at a temperature about 40° C. and under stirring, oxaliplatin in a solution of an excipient such as lactose monohydate in sterile water, then filtering once for clarification and one or more times for sterilisation, aliquoting the filtrate solution into vials and performing freeze-drying using cycles of freezing, primary drying (sublimation) and secondary drying according to techniques well known in the art.
- The weight content of oxalic acid in the lyophilisate pharmaceutical formulation is preferably not more than 0.60%, more preferably not more than 0.30%, most preferably not more than 0.20%.
- The pharmaceutical composition may also be a liquid pharmaceutical formulation for parenteral administration. Such a formulation is generally obtained by completely dissolving oxaliplatin in sterile water, at a temperature about 40° C. and under stirring, then filtering once for clarification and one or more times for sterilisation, as described in PCT Patent Publication No. 96/04904.
- The weight content of oxalic acid in the liquid pharmaceutical formulation is preferably not more than 0.60%, more preferably not more than 0.30%, in particular not more than 0.20%.
- The pharmaceutical composition may also be a sustained release formulation including biodegradable polymeric material, notably in the form of microparticles, microspheres, microgranules, implants or gels. Preparation of such an oxaliplatin sustained release formulation may be performed according to techniques well known in the art, with the limitation that all steps must be performed at a pH where the oxaliplatin active substance is stable, preferably between 4,5 and 7.0. An example of an appropriate method for preparing a sustained release formulation of microspheres is the process for preparing oxaliplatin encapsulating poly(D,L-lactide-co-glycolide)/poly(D,L-lactide) (PLGA/PLA) microspheres described in PCT Patent Publication No. 02/28386.
- The examples which follow will serve to better describe the invention, but are in no way to be considered as limitative.
- Preparation of an oxaliplatin active substance with a very low content of oxalic acid by applying modifications of the method described in U.S. Pat. No. 5,290,961 562.5 g of potassium chloroplatinate and 154.8 g of trans/-1,2-cyclohexane-diamine were dissolved and mixed in 3.5 litres of water to obtain cake-like cis-dichloro(trans-/-1,2-cyclohexanediamine)-platinum (II) without recrystallisation. The latter compound was suspended in 5.7 litres of water to which was added a solution which had been prepared by dissolving 386.4 g of silver nitrate in 2.8 litres of water. After this solution was stirred in the dark at room temperature for three days, most of the precipitate of silver chloride was removed by filtration. After the filtrate was concentrated under reduced pressure, a solution consisting of 45 ml of water and 3.85 g of potassium iodide dissolved therein was added followed by one hour stirring, and then active carbon was added. Silver iodido and iodine compounds then formed and the active carbon were completely removed by filtration. To the remaining filtrate was added 299.4 g of potassium oxalate monohydrate which was allowed to stand for two hours to obtain crude crystals of desired cis-oxalate (trans/-1,2-cyclohexanediamine)-platinum (II) which were collected by filtration and washed twice with 200 ml of sterile water of pH 5.9. Then, 65 g of this crude crystal was dissolved under heating in 2.7 litres of water, filtered and cooled to room temperature. The platinum crystals precipitated were collected by filtration and washed four times with 150 ml of water of pH 6.5. The crystals obtained were dried thereby yielding 309 g of oxaliplatin active substance.
- The weight content of oxalic acid in the oxaliplatin active substance was determined using a hereafter briefly described specific ion-pair reverse phase HPLC test which has a detection limit of 0.02 w/w % for oxalic acid. The test solution consists of oxaliplatin dissolved using sonication at the concentration of 2 mg/ml in water. The specific ion-pair reverse phase HPLC test is conducted at pH 6.0±0.05 and a temperature of 40° C. on a glass column of diameter 4.6 mm and length 25 cm containing a base-deactivated octadecylsilyl silica gel for chromatography, with a mobile phase consisting of 20 volumes of acetonitrile and 80 ml of a solution prepared by adding 1.36 g potassium dihydrogen phosphate to 10 ml 0.4 M tetrabutylammonium hydroxide and adjusting the pH to 6.0±0.05 with phosphoric acid, a flow rate of 2 ml/minute and UV detection at 205 nm.
- No oxalic acid was detected, corresponding to a weight content of oxalic acid below w/w 0.02% for the oxaliplatin active substance.
- Preparation of an oxaliplatin active substance according to one of the methods described in EP Patent Application No. 625523
- Potassium tetrachloroplatinate (3.40 g) was stirred at room temperature with trans-/-1,2-cyclohexanediamine (0.94 g) in aqueous solution (80 ml). The clear orange solution present at the onset of the reaction rapidly turned yellow with a precipitate beginning to form after 30 minutes. The reaction mixture was stirred overnight (14 hours) and filtered. The yellow precipitate was washed with water and dried under vacum. The crude obtained product (2.98 g) was recrystallised from 6 litres of boiling 0.1N HCl. Upon cooling to room temperature, crystals of dichloro-(trans-/-1,2-cyclohexanediamine)-platinum (II) (2.33 g) were collected by filtration. In parallel, an aqueous solution of oxalic acid (1.29 g, in 10 ml of water) was added dropwise to an aqueous suspension of silver carbonate (2.64 g, in 10 ml of water). Upon stirring 15 minutes at room temperature, carbon dioxide evolution ceased, suggesting a quantitative formation of silver oxalate. The off-white precipitate was collected by filtration. The filtrate was washed abundantly with water and dried under vacum. To an aqueous suspension of dichloro (trans-/-1,2-cyclohexanediamine)-platinum (II) (1.5 g, in 120 ml of water) as obtained above, silver oxalate (1.199 g) was added as a solid and stirred for 4 hours at room temperature in the dark. With time, the yellow suspension became paler. The precipitate silver chloride was removed by filtration. The resulting clear solution was concentrated to 15 ml to yield a yellow precipitate. After standing at room temperature for 1 hour, the pale yellow precipitate was collected by filtration, yielding to cis-oxalato (trans-/-1,2-cyclohexane-diamine)-platinum (II).
- A sample has been analysed by applying the above-described HPLC method and oxalic acid was detected, corresponding to a weight content of oxalic acid of w/w 0.19% for the oxaliplatin active substance.
- Preparation of a pharmaceutical composition in the form of a liquid formulation for parenteral administration using the oxaliplatin active substance of the invention
- In a glass or inox container equipped with a thermostat, about 80% of the desired sterile water are introduced and the temperature is brought under stirring (800-1200 rpm) to a temperature of 40±5° C.
- The amount of oxaliplatin active substance (as obtained in Example 1) necessary to obtain a final concentration for example of 5 mg/ml is separately weighed, then added in preheated sterile water to the sterile water in the glass or inox container. The weighing container is rinsed three times with sterile water, the rinsing solution being added to the above mixture. The latter is stirred at the above temperature during 30 to 60 minutes, until complete dissolution of oxaliplatin. Optionally the water is bubbled with nitrogen to lower its oxygen content.
- The volume or weight of the solution is adjusted to its desired value by adding sterile water. The solution is stirred at 40±5° C. during about 10 minutes then cooled to 30° C. under stirring. Samples of the solution are then collected for the usual control tests. The solution is then subjected to aseptic filtration on a 0.2 μm membrane or alternatively autoclaving under conditions close to those described in European Pharmacopia 1997 Edition page 283-284 (minimum of 121° C. for 15 minutes). The solution is kept at 15-30° C. before being conditioned.
- The oxaliplatin solution for example at 5 mg/ml is then aseptically and preferably under nitrogen atmosphere conditioned in 5 ml cylindrical vials (volume of added solution about 4 ml corresponding to 20 mg available oxaliplatin), 15 ml cylindrical vials (volume of added solution about 10 ml corresponding to 50 mg available oxaliplatin), and 25 ml cylindrical vials (volume of added solution about 20 ml corresponding to 100 mg available oxaliplatin).
- Those vials are kept during 12 months partly in an incubator at 25° C. and a relative humidity of 60% and partly in an incubator at 40° C. and a relative humidity of 75%.
- Preparation of a pharmaceutical composition in the form of a lyophilisate for parenteral administration using the oxaliplatin active substance of the invention.
- In a glass or inox container equipped with a thermostat, about 80% of the desired sterile water are introduced and the temperature is brought under stirring (800-1200 rpm) to a temperature of 38±5° C. Lactose monohydrate is added under stirring until a final concentration of 45 mg/ml.
- The amount of oxaliplatin active substance (as obtained in Example 1) necessary to obtain a final concentration for example of 5 mg/ml is separately weighed, then added in preheated sterile water to the sterile water in the glass or inox container. The weighing container is rinsed three times with sterile water, the rinsing solution being added to the above mixture. The latter is stirred at the above temperature during 30 to 60 minutes, until complete dissolution of oxaliplatin. Optionally the water is bubbled with nitrogen to lower its oxygen content.
- The volume or weight of the solution is adjusted to its desired value by adding sterile water. The solution is stirred at 40±5° C. during about 10 minutes then cooled to 15-30° C. under stirring. Samples of the solution are then collected for the usual control tests. The solution is subjected to aseptic filtration on a 0.2 μm membrane, then aseptically filled into 50 ml cylindrical vials to give 100 mg oxaliplatin per vial. Freeze-drying is performed using cycles of freezing, primary drying (sublimation) and secondary drying, according to techniques well known in the art. The vials containing the lyophilisate pharmaceutical formulation are stoppered and sealed.
- Evaluation of the relative toxicity due to the presence of oxalic acid in oxaliplatin active substance—Determination of lethal doses LD10
- Lethal doses LD10 of a cytostatic active substance determinated in mice is generally considered as being a significative correlation with the maximum tolerated doses (MTD) in man.
- Accordingly, a first group of CD-1 mice has received a solution of the oxaliplatin active substance as obtained in Example 1 and LD10 is around 18.0 mg7kg.
- A second group of animals has received the same solution as for the first group, but with the addition of oxalic acid at a final concentration of 0.2 mM, and LD10 is around 14.4.
- Finally, a control group has only received a solution of oxalic acid at a concentration of 0.2 mM and no significant toxicity has been observed.
- LD10 along with clinical symptoms demonstrate that the oxaliplatin active substance as obtained in Example 4, while administrated in solution, is less toxic as the same active substance, but administrated with oxalic acid.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/576,383 US8211940B2 (en) | 2001-07-02 | 2009-10-09 | Oxaliplatin active substance with a very low content of oxalic acid |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH0100414 | 2001-07-02 | ||
WOPCT/CH01/00414 | 2001-07-02 | ||
CH0100618 | 2001-10-15 | ||
WOPCT/CH01/00618 | 2001-10-15 | ||
PCT/CH2002/000358 WO2003004505A1 (en) | 2001-07-02 | 2002-07-02 | Oxaliplatin active substance with a very low content of oxalic acid |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/576,383 Continuation US8211940B2 (en) | 2001-07-02 | 2009-10-09 | Oxaliplatin active substance with a very low content of oxalic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040186172A1 true US20040186172A1 (en) | 2004-09-23 |
Family
ID=25705682
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/482,367 Abandoned US20040186172A1 (en) | 2001-07-02 | 2002-07-02 | Oxaliplatin active substance with a very low content of oxalic acid |
US12/576,383 Expired - Lifetime US8211940B2 (en) | 2001-07-02 | 2009-10-09 | Oxaliplatin active substance with a very low content of oxalic acid |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/576,383 Expired - Lifetime US8211940B2 (en) | 2001-07-02 | 2009-10-09 | Oxaliplatin active substance with a very low content of oxalic acid |
Country Status (3)
Country | Link |
---|---|
US (2) | US20040186172A1 (en) |
EP (1) | EP1404689A1 (en) |
WO (1) | WO2003004505A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1674105A1 (en) * | 2004-12-23 | 2006-06-28 | Stada Arzneimittel Ag | Ready to use gemcitabine solutions and concentrates |
US20060216360A1 (en) * | 2005-03-28 | 2006-09-28 | Dabur Pharma Ltd. | Stable pharmaceutical compositions of platinum (II) antitumour agents |
US20070054957A1 (en) * | 2005-09-05 | 2007-03-08 | Dabur Pharma Limited | Stable oxaliplatin formulation |
CN100372858C (en) * | 2006-07-10 | 2008-03-05 | 江苏奥赛康药业有限公司 | Method for refining oxaliplatin |
US20090281319A1 (en) * | 2006-01-30 | 2009-11-12 | Platco Technologies (Proprietary) Limited | Preparation of platinum (ii) complexes |
US20090299085A1 (en) * | 2004-09-01 | 2009-12-03 | Platco Technologies (Proprietary) Limited | Preparation of platinum(ii) complexes |
US20090312417A1 (en) * | 2003-11-25 | 2009-12-17 | Platco Technologies (Proprietary) Limited | Platinum(ii) complexes, preparation and use |
US7829113B2 (en) | 2005-03-10 | 2010-11-09 | Mebiopharm Co., Ltd. | Liposome compositions |
US8637692B2 (en) | 2009-06-26 | 2014-01-28 | Umicore Ag & Co. Kg | Process for preparation of 1,2-diamino-cyclohexane-platinum (II) complexes |
WO2019157370A1 (en) * | 2018-02-09 | 2019-08-15 | Decibel Therapeutics, Inc. | Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent |
US10813947B1 (en) | 2019-05-31 | 2020-10-27 | Decibel Therapeutics, Inc. | Methods of otoprotection against platinum-based antineoplastic agents |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10314377A1 (en) * | 2003-03-28 | 2004-10-07 | Stada Arzneimittel Ag | Pharmaceutical composition useful for tumor therapy comprises water, oxaliplatin and an acid other than oxalic acid |
CZ297703B6 (en) * | 2003-10-17 | 2007-03-07 | Pliva-Lachema A.S. | Oxaliplatin with low content of accompanying impurities and process for preparing thereof |
US7608730B2 (en) | 2004-02-05 | 2009-10-27 | Fresenius Kabi Oncology Limited | Process for the preparation of an anti-tumor platinum (II)—complex |
DE102004005906B3 (en) * | 2004-02-05 | 2005-09-29 | W.C. Heraeus Gmbh | Process for the preparation of 1,2-diaminocylohexane-platinum (II) complexes |
JP2008504292A (en) | 2004-06-24 | 2008-02-14 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | Immune enhancement compounds |
WO2006023154A1 (en) | 2004-07-12 | 2006-03-02 | Sicor, Inc. | Cis-diiodo- (trans-l-1,2-cyclohexanediamine) platinum (ii) complex and processes for preparing high purity oxaliplatin |
US7605282B2 (en) | 2005-04-09 | 2009-10-20 | Vuab Pharma A.S. | Process for the preparation of an oxaliplatin preparation |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | PI-3 Kinase inhibitors and methods of their use |
AR060358A1 (en) | 2006-04-06 | 2008-06-11 | Novartis Vaccines & Diagnostic | QUINAZOLINS FOR THE INHIBITION OF PDK 1 |
CN100398550C (en) * | 2006-04-18 | 2008-07-02 | 昆明贵研药业有限公司 | Novel process for synthesis of oxaliplatin as anticancer medicine |
ES2353531T3 (en) | 2006-06-08 | 2011-03-02 | Vuab Pharma A. S. | PROCEDURE FOR THE PREPARATION OF AN OXALIPLATIN. |
CA2710122A1 (en) | 2007-12-20 | 2009-07-02 | Novartis Ag | Thiazole derivatives used as pi 3 kinase inhibitors |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
CA2786294A1 (en) | 2010-02-22 | 2011-08-25 | F. Hoffmann-La Roche Ag | Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use |
AR082418A1 (en) | 2010-08-02 | 2012-12-05 | Novartis Ag | CRYSTAL FORMS OF 1- (4-METHYL-5- [2- (2,2,2-TRIFLUORO-1,1-DIMETHYL-Ethyl) -PIRIDIN-4-IL] -TIAZOL-2-IL) -AMIDE OF 2 -AMIDA OF THE ACID (S) -PIRROLIDIN-1,2-DICARBOXILICO |
PL2670753T3 (en) | 2011-01-31 | 2017-05-31 | Novartis Ag | Novel heterocyclic derivatives |
AP2014007601A0 (en) | 2011-10-28 | 2014-04-30 | Novartis Ag | Novel purine derivatives and their use in the treatment of disease |
CA2872526A1 (en) | 2012-05-16 | 2013-11-21 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
US20170000778A1 (en) | 2013-12-06 | 2017-01-05 | Emmanuelle di Tomaso | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor |
CN104945443A (en) * | 2015-07-23 | 2015-09-30 | 青岛蓝盛洋医药生物科技有限责任公司 | Drug, namely oxaliplatin compound, for treating cancer |
CN104940151A (en) * | 2015-07-23 | 2015-09-30 | 青岛蓝盛洋医药生物科技有限责任公司 | Oxaliplatin freeze-dried powder injection composition as anti-cancer drug |
MX2018005298A (en) | 2015-11-02 | 2018-06-22 | Novartis Ag | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor. |
WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4169846A (en) * | 1976-09-06 | 1979-10-02 | Kenji Inagaki | Cis-platinum (ii) complex of trans-l-1,2-diaminocyclohexane |
US5104896A (en) * | 1989-06-06 | 1992-04-14 | Pharmachemie B.V. | Carboplatin composition |
US5290961A (en) * | 1992-01-13 | 1994-03-01 | Tanaka Kikinzoku Kogyo K.K. | Platinum compound and process of preparing same |
US5298642A (en) * | 1992-04-22 | 1994-03-29 | Tanaka Kikinzoku Kogyo K.K. | Process of optically resoluting optically active platinum complex compound |
US5338874A (en) * | 1993-01-12 | 1994-08-16 | Tanaka Kikinzoku Kogyo K.K. | Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) having optically high purity |
US5420319A (en) * | 1993-05-21 | 1995-05-30 | Tanaka Kikinzoku Kogyo K.K. | Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same |
US5716988A (en) * | 1994-08-08 | 1998-02-10 | Debiopharm S.A. | Pharmaceutically stable preparation of oxaliplatinum |
US5959133A (en) * | 1996-07-04 | 1999-09-28 | Tanaka Kikinzoku Kogyo K.K. | Process for the preparation of platinum compounds |
US6396902B2 (en) * | 2000-07-31 | 2002-05-28 | Analogic Corporation | X-ray collimator |
US6476068B1 (en) * | 2001-12-06 | 2002-11-05 | Pharmacia Italia, S.P.A. | Platinum derivative pharmaceutical formulations |
US6866857B1 (en) * | 1998-10-14 | 2005-03-15 | Debiopharm S.A. | Oxalipatinum preparation packaging |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US625523A (en) | 1899-05-23 | Perry c | ||
US801070A (en) | 1905-05-03 | 1905-10-03 | Frank Quinn Fokes | Guano-distributer. |
EP0801070B1 (en) | 1996-04-10 | 2003-04-16 | Debiopharm S.A. | Process of preparing platinum compound |
GB9804013D0 (en) * | 1998-02-25 | 1998-04-22 | Sanofi Sa | Formulations |
US7605282B2 (en) * | 2005-04-09 | 2009-10-20 | Vuab Pharma A.S. | Process for the preparation of an oxaliplatin preparation |
ES2353531T3 (en) * | 2006-06-08 | 2011-03-02 | Vuab Pharma A. S. | PROCEDURE FOR THE PREPARATION OF AN OXALIPLATIN. |
-
2002
- 2002-07-02 EP EP02734974A patent/EP1404689A1/en not_active Withdrawn
- 2002-07-02 WO PCT/CH2002/000358 patent/WO2003004505A1/en not_active Application Discontinuation
- 2002-07-02 US US10/482,367 patent/US20040186172A1/en not_active Abandoned
-
2009
- 2009-10-09 US US12/576,383 patent/US8211940B2/en not_active Expired - Lifetime
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4169846A (en) * | 1976-09-06 | 1979-10-02 | Kenji Inagaki | Cis-platinum (ii) complex of trans-l-1,2-diaminocyclohexane |
US5104896A (en) * | 1989-06-06 | 1992-04-14 | Pharmachemie B.V. | Carboplatin composition |
US5290961A (en) * | 1992-01-13 | 1994-03-01 | Tanaka Kikinzoku Kogyo K.K. | Platinum compound and process of preparing same |
US5298642A (en) * | 1992-04-22 | 1994-03-29 | Tanaka Kikinzoku Kogyo K.K. | Process of optically resoluting optically active platinum complex compound |
US5338874A (en) * | 1993-01-12 | 1994-08-16 | Tanaka Kikinzoku Kogyo K.K. | Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) having optically high purity |
US5420319A (en) * | 1993-05-21 | 1995-05-30 | Tanaka Kikinzoku Kogyo K.K. | Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same |
US5716988A (en) * | 1994-08-08 | 1998-02-10 | Debiopharm S.A. | Pharmaceutically stable preparation of oxaliplatinum |
US5959133A (en) * | 1996-07-04 | 1999-09-28 | Tanaka Kikinzoku Kogyo K.K. | Process for the preparation of platinum compounds |
US6866857B1 (en) * | 1998-10-14 | 2005-03-15 | Debiopharm S.A. | Oxalipatinum preparation packaging |
US6396902B2 (en) * | 2000-07-31 | 2002-05-28 | Analogic Corporation | X-ray collimator |
US6476068B1 (en) * | 2001-12-06 | 2002-11-05 | Pharmacia Italia, S.P.A. | Platinum derivative pharmaceutical formulations |
US20030109514A1 (en) * | 2001-12-06 | 2003-06-12 | Pharmacia Italia, S.P.A. | Platinum derivative pharmaceutical formulations |
US20030109515A1 (en) * | 2001-12-06 | 2003-06-12 | Pharmacia Italia, Spa. | Pharmaceutical formulation of a platinum derivative |
US6673805B2 (en) * | 2001-12-06 | 2004-01-06 | Pharmacia Italia S.P.A. | Platinum derivative pharmaceutical formulations |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090312417A1 (en) * | 2003-11-25 | 2009-12-17 | Platco Technologies (Proprietary) Limited | Platinum(ii) complexes, preparation and use |
US7888390B2 (en) | 2003-11-25 | 2011-02-15 | Platco Technologies (Proprietary) Limited | Preparation of platinum(II) complexes |
US7888523B2 (en) | 2004-09-01 | 2011-02-15 | Platco Technologies (Proprietary) Limited | Preparation of platinum(II) complexes |
US20090299085A1 (en) * | 2004-09-01 | 2009-12-03 | Platco Technologies (Proprietary) Limited | Preparation of platinum(ii) complexes |
US20060154891A1 (en) * | 2004-12-23 | 2006-07-13 | Edgar Schridde | Ready-to-use gemcitabine solutions and gemcitabin concentrates |
EP1674105A1 (en) * | 2004-12-23 | 2006-06-28 | Stada Arzneimittel Ag | Ready to use gemcitabine solutions and concentrates |
US8758810B2 (en) | 2005-03-10 | 2014-06-24 | Mebiopharm Co., Ltd. | Liposome compositions |
US7829113B2 (en) | 2005-03-10 | 2010-11-09 | Mebiopharm Co., Ltd. | Liposome compositions |
US20060216360A1 (en) * | 2005-03-28 | 2006-09-28 | Dabur Pharma Ltd. | Stable pharmaceutical compositions of platinum (II) antitumour agents |
US20070054957A1 (en) * | 2005-09-05 | 2007-03-08 | Dabur Pharma Limited | Stable oxaliplatin formulation |
US7674824B2 (en) * | 2005-09-05 | 2010-03-09 | Fresenius Kabi Oncology Limited | Stable oxaliplatin formulation |
US20090281319A1 (en) * | 2006-01-30 | 2009-11-12 | Platco Technologies (Proprietary) Limited | Preparation of platinum (ii) complexes |
US7956208B2 (en) | 2006-01-30 | 2011-06-07 | Platco Technologies (Proprietary) Limited | Preparation of platinum (II) complexes |
CN100372858C (en) * | 2006-07-10 | 2008-03-05 | 江苏奥赛康药业有限公司 | Method for refining oxaliplatin |
US8637692B2 (en) | 2009-06-26 | 2014-01-28 | Umicore Ag & Co. Kg | Process for preparation of 1,2-diamino-cyclohexane-platinum (II) complexes |
WO2019157370A1 (en) * | 2018-02-09 | 2019-08-15 | Decibel Therapeutics, Inc. | Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent |
US10709732B2 (en) | 2018-02-09 | 2020-07-14 | Decibel Therapeutics, Inc. | Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent |
US11071751B2 (en) | 2018-02-09 | 2021-07-27 | Decibel Therapeutics, Inc. | Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent |
US11857567B2 (en) | 2018-02-09 | 2024-01-02 | Decibel Therapeutics, Inc. | Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent |
US10813947B1 (en) | 2019-05-31 | 2020-10-27 | Decibel Therapeutics, Inc. | Methods of otoprotection against platinum-based antineoplastic agents |
US11690870B2 (en) | 2019-05-31 | 2023-07-04 | Decibel Therapeutics, Inc. | Methods of otoprotection against platinum-based antineoplastic agents |
Also Published As
Publication number | Publication date |
---|---|
WO2003004505A1 (en) | 2003-01-16 |
US20100173988A1 (en) | 2010-07-08 |
EP1404689A1 (en) | 2004-04-07 |
US8211940B2 (en) | 2012-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8211940B2 (en) | Oxaliplatin active substance with a very low content of oxalic acid | |
EP2244712B1 (en) | In vivo studies of crystalline forms of meloxicam | |
TWI394774B (en) | Novel block copolymers, microcell modifiers, and anticancer agents that are useful as an active ingredient | |
ES2568475T3 (en) | Morphinan derivative crystals and process for producing them | |
JP2017526699A (en) | Composition of (6S) -5-methyltetrahydrofolic acid or its salt and its preparation and application | |
CN109620799B (en) | Stable bromhexine hydrochloride liquid preparation composition and preparation method thereof | |
JP2004510778A (en) | Platinum complexes as antitumor agents | |
RU2203901C2 (en) | Platinum complex compounds, methods of their synthesis, pharmaceutical composition | |
JPH09511991A (en) | Donkey platinum trihydrate | |
FI88165C (en) | Process for the preparation of cis-diammine-1,1-cyclobutanedicarboxylate-platinum (II) complex | |
WO2009090903A1 (en) | Platinum complex compound and utilization of the same | |
CN109574919B (en) | Etoricoxib purification and preparation method | |
EP0923932B1 (en) | Composition containing antitumor agent | |
CN102351881B (en) | Stable levofloxacin hydrochloride compound | |
US20170275319A1 (en) | Platinum derivatives for hydrophobic formulations | |
EP1194438B1 (en) | Nitrates of bis-platinum complexes with polyamine | |
DE20221678U1 (en) | Preparation of an oxaliplatin active substance, useful in the treatment of cancer and comprising a very low content of oxalic acid | |
EP2947069B1 (en) | Sulfate of 5-hydroxy-1h-imidazole-4-carboxamide | |
RU2054286C1 (en) | Platinum cytostatic agent and a method of its producing | |
CN104945381B (en) | A kind of fasudil hydrochloride compound, preparation method and its pharmaceutical composition | |
CN114681465A (en) | Lobaplatin-flavone pharmaceutical co-crystal as well as preparation method and application thereof | |
RU2391334C2 (en) | Water-soluble complex of cis-diaminodichloroplatinum (2+) with isoniaside and method of preparing said complex | |
CA2247329C (en) | Composition containing antitumor agent | |
JPH0867688A (en) | New platinum complex | |
JP2003525283A (en) | Ranitidine isomer isomer Z hydrochloride |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DEBIOPHARM S.A., SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:IBRAHIM, HOUSSAM;REEL/FRAME:015352/0801 Effective date: 20031210 |
|
AS | Assignment |
Owner name: DEBIOPHARM S.A., SWITZERLAND Free format text: CHANGE OF ADDRESS;ASSIGNOR:DEBIOPHARM S.A.;REEL/FRAME:016627/0352 Effective date: 20050124 |
|
AS | Assignment |
Owner name: DEBIOPHARM S.A., SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MAUVERNAY, ROLLAND-YVES;REEL/FRAME:018795/0834 Effective date: 20061213 |
|
AS | Assignment |
Owner name: DEBIOPHARM S.A., SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MAUVERNAY, ROLLAND-YVES;REEL/FRAME:018830/0839 Effective date: 20061213 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |